BRPI0414049A - compostos e composições como inibidores de proteìna cinase - Google Patents
compostos e composições como inibidores de proteìna cinaseInfo
- Publication number
- BRPI0414049A BRPI0414049A BRPI0414049-4A BRPI0414049A BRPI0414049A BR PI0414049 A BRPI0414049 A BR PI0414049A BR PI0414049 A BRPI0414049 A BR PI0414049A BR PI0414049 A BRPI0414049 A BR PI0414049A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- sapk2
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 2
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 2
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 101150046814 SAPK2 gene Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
- 101150036586 FES gene Proteins 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 abstract 1
- 101150028321 Lck gene Proteins 0.000 abstract 1
- 101100272634 Mus musculus Bmx gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 abstract 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS E COMPOSIçõES COMO INIBIDORES DE PROTEìNA CINASE". A presente invenção fornece uma nova classe de compostos, composições farmacêuticas compreendendo tais compostos e métodos de emprego de tais compostos para tratar ou prevenir doenças ou distúrbios associados com atividade de cinase anormal ou desregulada, particularmente doenças ou distúrbios que envolvem a ativação anormal das Abl, BCRAbl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2<244> e SAPK2<225> cinases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49853203P | 2003-08-28 | 2003-08-28 | |
| PCT/US2004/027997 WO2005039486A2 (en) | 2003-08-28 | 2004-08-27 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414049A true BRPI0414049A (pt) | 2006-10-24 |
Family
ID=34519982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414049-4A BRPI0414049A (pt) | 2003-08-28 | 2004-08-27 | compostos e composições como inibidores de proteìna cinase |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7338957B2 (pt) |
| EP (1) | EP1658290A4 (pt) |
| JP (1) | JP2007504159A (pt) |
| CN (1) | CN100439365C (pt) |
| AU (1) | AU2004283093B2 (pt) |
| BR (1) | BRPI0414049A (pt) |
| CA (1) | CA2536535A1 (pt) |
| MX (1) | MXPA06002347A (pt) |
| WO (1) | WO2005039486A2 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202873D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| ATE492545T1 (de) * | 2005-05-13 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinase-hemmer |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| JP5680850B2 (ja) | 2006-03-30 | 2015-03-04 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラThe University Court of the University of Edinburgh | キナーゼインヒビターを含む培養培地およびその使用 |
| WO2007116029A2 (en) | 2006-04-07 | 2007-10-18 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
| WO2008147831A1 (en) * | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
| EP2178880B1 (en) * | 2007-08-02 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of e1 activating enzyme inhibitors |
| ES2424977T3 (es) * | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| EP2222162B1 (en) | 2007-11-28 | 2016-11-16 | Dana-Farber Cancer Institute, Inc. | Small molecule myristate inhibitors of bcr-abl and methods of use |
| BRPI0907236A2 (pt) * | 2008-01-22 | 2017-06-06 | Merck Patent Ges Mit Berschränkter Haftung | inibidores de proteína quinase e uso dos mesmos |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| US9187482B2 (en) | 2009-05-14 | 2015-11-17 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| US8728763B2 (en) | 2009-08-11 | 2014-05-20 | Response Genetics | Methods, primers, probes and kits useful for the detection of BRAF mutations |
| JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN104876879B (zh) * | 2015-04-14 | 2018-05-18 | 中国科学院合肥物质科学研究院 | 一种bcr-abl激酶抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531558T2 (de) * | 1995-06-07 | 2004-03-18 | Pfizer Inc. | Heterocyclische kondensierte pyrimidin-derivate |
| TR200101186T2 (tr) * | 1998-09-18 | 2001-10-22 | Basf Aktiengesellschaft | Protein kinaz engelleyiciler olarak pyrrolopyrimidin'ler |
| EP1244672B1 (en) * | 1999-12-21 | 2005-07-20 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
-
2004
- 2004-08-26 US US10/927,992 patent/US7338957B2/en not_active Expired - Fee Related
- 2004-08-27 WO PCT/US2004/027997 patent/WO2005039486A2/en not_active Ceased
- 2004-08-27 EP EP04816834A patent/EP1658290A4/en not_active Withdrawn
- 2004-08-27 CN CNB2004800245751A patent/CN100439365C/zh not_active Expired - Fee Related
- 2004-08-27 AU AU2004283093A patent/AU2004283093B2/en not_active Ceased
- 2004-08-27 CA CA002536535A patent/CA2536535A1/en not_active Abandoned
- 2004-08-27 MX MXPA06002347A patent/MXPA06002347A/es active IP Right Grant
- 2004-08-27 JP JP2006524903A patent/JP2007504159A/ja active Pending
- 2004-08-27 BR BRPI0414049-4A patent/BRPI0414049A/pt not_active IP Right Cessation
-
2008
- 2008-01-07 US US11/970,278 patent/US20080108616A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080108616A1 (en) | 2008-05-08 |
| AU2004283093A1 (en) | 2005-05-06 |
| US7338957B2 (en) | 2008-03-04 |
| WO2005039486A2 (en) | 2005-05-06 |
| JP2007504159A (ja) | 2007-03-01 |
| CN1842529A (zh) | 2006-10-04 |
| CN100439365C (zh) | 2008-12-03 |
| CA2536535A1 (en) | 2005-05-06 |
| MXPA06002347A (es) | 2006-05-19 |
| WO2005039486A3 (en) | 2006-03-16 |
| EP1658290A2 (en) | 2006-05-24 |
| EP1658290A4 (en) | 2009-04-15 |
| US20050159391A1 (en) | 2005-07-21 |
| AU2004283093B2 (en) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| BRPI0511978A (pt) | compostos e composições como inibidores de proteìnas quinases | |
| BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
| BRPI0507668A (pt) | compostos e composições como inibidores de proteìna cinase | |
| DE602006014540D1 (en) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| BRPI0414930A (pt) | compostos e composições como inibidores de proteìnas cinases | |
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| BRPI0409173A (pt) | compostos e composições como inibidores de proteìna quinase | |
| BRPI0413005A (pt) | compostos e composições como inibidores da proteìna cinase | |
| WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| BRPI0517015A (pt) | compostos e composições como inibidores de atividade de receptor 1 de canabinóide | |
| TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
| BRPI0719797A8 (pt) | Compostos e composições como inibidores de proteína cinase | |
| BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
| WO2006101783A8 (en) | Compounds and compositions as protein kinase inhibitors | |
| BRPI0414794A (pt) | oxadiazolidinadionas substituìdas | |
| BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
| BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
| MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
| BRPI0414869A (pt) | compostos e composições como inibidores da proteìna quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. C07D 471/04, 487/04; A61K 31/519, 31/4355; A61P 35/00 Ipc: C07D 471/04 (2011.01), C07D 487/04 (2011.01), A61K |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |